Clinical TrialsSEP-786 was discontinued due to unexpected, off-target toxicity in 2 MAD patients, but the adverse effect was reversible and did not lead to liver injury.
Development PipelineA new development candidate for the PTH program has not been selected, leading to a removal of value from the program.
Stock PerformanceThe stock may trade down sharply as SEP-786 was SEPN's lead program and nearest data catalyst.